Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santhera Pharmaceuticals AG

www.santhera.com

Latest From Santhera Pharmaceuticals AG

Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber

Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.

Deals Business Strategies

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.

Deals Business Strategies

Santhera Shores Up Finances With Chiesi Deal for Raxone

In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.

Rare Diseases Companies

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Graffinity Pharmaceuticals AG
  • MyoContract Pharmaceutical Research Ltd.
  • Graffinity Pharmaceutical Design GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Santhera Pharmaceuticals AG
  • Senior Management
  • Thomas Meier, PhD, CEO
    Christoph Rentsch, CFO
    Gunther Metz, EVP, Head Bus. Dev.
    Kristina Sjöblom Nygren, CMO & EVP, Head Dev.
  • Contact Info
  • Santhera Pharmaceuticals AG
    Phone: (41) 61 906 89 50
    Hohenrainstrasse 24
    Pratteln, 4133
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register